MedTrace Logo

Supraclavicular Brachial Plexus Block Using Ropivacaine Alone and With Dexmedetomidine

NCT02393677 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2015-11-06

Study results available
· View outcomes & findings →

Summary

80 American Society of Anesthesiologists (ASA) grade I-II patients, 18-60 years old,scheduled for elective upper limb orthopaedic surgery under supraclavicular brachial plexus block, were included in this prospective study. The patients were randomly assigned to group R (Ropivacaine alone) and group RD (Ropivacaine and dexmedetomidine) (40 patients in each group). Group R received Ropivacaine 0.50% (30 cc) + placebo and group RD received Ropivacaine 0.50% (30 cc) + dexmedetomidine 1 µg/kg.

Conditions

  • Brachial Plexus Anesthesia

Interventions

DRUG

Ropivacaine

Ropivacaine 0.5% 30 ml was used to block brachial plexus

DRUG

Ropivacaine with Dexmedetomidine

Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus

Sponsors & Collaborators

  • Government Medical College, Haldwani

    lead OTHER

Principal Investigators

  • Shahin N Jamil, MD · Professor, Aligarh Muslim University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-07-31
Completion
2012-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02393677 on ClinicalTrials.gov